Top 20 genes with significantly decreased abundance in Aco^R cells. by Pieter C. Steketee (10024552)

Subjects:

Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width. by Maral Budak (6680351)

“…The latencies of the CAP peaks did not exhibit any significant difference between different populations for all sound levels.…”

Case of normal load changing. by Basem Abd-Elhamed Rashad (17781467)

Subjects:

GO analysis of stage-salient genes in the order of decreasing significance (i.e, increasing p–value). by Sangeetha Muthamilselvan (8966006)

Subjects:

The relative change in incident cases of RA among AYAs between 1990 and 2019. by Ruibo Li (2063167)

Subjects:

Roughness change in means of Ra (nm) and RMS (nm) for both tested systems. (different capital superscript letters indicate within group significancy, different lower-case superscript letters indicate significancy between groups). by Beliz Özel (16475132)

“…(different capital superscript letters indicate within group significancy, different lower-case superscript letters indicate significancy between groups).…”

Results of RF regression model validation and significance of influencing factors (desert area change and spatiotemporal characteristics of ERI). by Mingyue Sun (4638535)

Significant Lipids by Category- Tiers 1 and 2. by Keenan Elliott (17181211)

Subjects:

NN analysis to assign the importance of variables. by Sulmaz Ghahramani (3387635)

Subjects:

Significant lipids by category-Tiers 1, 2, and 3. by Keenan Elliott (17181211)

Subjects:

Metabolites elevated significantly in Aco^R cells. by Pieter C. Steketee (10024552)

Subjects:

Frequencies of peripheral blood immune cells with each profile in all patients before and after OBV/PTV/r therapy that did not change significantly. by Miyabi Miura (18605126)

Subjects:

Estimated short- and long-term cumulative changes in CRC incidence and CRC mortality attributable to screening, diagnosis, and treatment decreases in 2020 and 2021. by Joachim Worthington (8394213)

Subjects:

Comparison of the statistical significance between t-tests with C₁ = 40 and CTOT with C₁ = 32. by Wei Zhuang (146641)

Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Case. by Seungyoon Paik (14659575)

Subjects:

Top 20 genes with significantly increased abundance in Aco^R cells. by Pieter C. Steketee (10024552)

Subjects:

Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”